These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 24585004

  • 21. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, Krivak TC, Niedernhofer LJ.
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [Abstract] [Full Text] [Related]

  • 22. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC.
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, Daraï E, Touboul C.
    Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
    [Abstract] [Full Text] [Related]

  • 25. Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.
    Liu SC, Lin H, Huang CC, Chang Chien CC, Tsai CC, Ou YC, Fu HC, Liu JM, Ma YY.
    Taiwan J Obstet Gynecol; 2016 Apr; 55(2):213-9. PubMed ID: 27125404
    [Abstract] [Full Text] [Related]

  • 26. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D, Zhang W, Li XG, Wang XB, Zhang LF, Li M, Li YF, Tian HM, Song PP, Liu J, Chang QY, Wu LY.
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [Abstract] [Full Text] [Related]

  • 27. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A.
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [Abstract] [Full Text] [Related]

  • 28. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA, Sabaa BE, Abdelkhalik D, Mansour H, Melis M, Shaalan W, Farouk M, Malik E, Soliman AA.
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [Abstract] [Full Text] [Related]

  • 29. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB, Mei Y, Tian ZW, Long J, Luo CH, Zhou HH.
    Cell Physiol Biochem; 2018 May; 46(5):1971-1984. PubMed ID: 29719287
    [Abstract] [Full Text] [Related]

  • 30. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
    Steffensen KD, Waldstrøm M, Brandslund I, Petzold M, Jakobsen A.
    Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
    [Abstract] [Full Text] [Related]

  • 31. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
    Li Y, Hu P, Cao Y, Wang GY, Wang N, Zhou RM.
    Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
    [Abstract] [Full Text] [Related]

  • 32. ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
    Ryu H, Song IC, Choi YS, Yun HJ, Jo DY, Kim JM, Ko YB, Lee HJ.
    Medicine (Baltimore); 2017 Dec; 96(51):e9402. PubMed ID: 29390553
    [Abstract] [Full Text] [Related]

  • 33. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
    Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.
    J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
    [Abstract] [Full Text] [Related]

  • 34. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [Abstract] [Full Text] [Related]

  • 35. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
    Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J.
    Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
    [Abstract] [Full Text] [Related]

  • 36. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S, Vusuratana A, Areepium N.
    Asian Pac J Cancer Prev; 2020 Jul 01; 21(7):1925-1929. PubMed ID: 32711417
    [Abstract] [Full Text] [Related]

  • 37. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.
    J Pathol; 2012 Apr 01; 226(5):746-55. PubMed ID: 22069160
    [Abstract] [Full Text] [Related]

  • 38. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 39. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 15; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 40. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
    Li L, Wu M, Yang JX, Wan XR, Huang HF, Pan LY, Shen K, Lang JH, Xiang Y.
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov 25; 51(11):825-831. PubMed ID: 27916065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.